Translational Development Acquisition Corp. (TDAC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Translational Development Acquisition Corp. (TDAC) trades at $10.84 with AI Score 43/100 (Grade C). Translational Development Acquisition Corp. is a shell company focused on identifying and merging with a private business. Market cap: $267M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for TDAC: TDAC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TDAC against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TDAC: 1/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Translational Development Acquisition Corp. (TDAC) Financial Services Profile
Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) aiming to identify and merge with a private entity, offering investors exposure to a potentially high-growth business through a public listing, operating within the financial services sector and incorporated in 2022.
What Is the Investment Thesis for TDAC?
Investing in Translational Development Acquisition Corp. (TDAC) is speculative, as its value depends entirely on the successful identification and merger with a private company. The company's market capitalization is $0.23 billion. A successful merger could lead to significant returns if the acquired company performs well in the public market. However, potential investors face risks, including the possibility that TDAC may not find a suitable target or that the acquired company may underperform expectations. The company's beta is -0.01. The investment thesis hinges on the management team's expertise in identifying and executing a value-accretive transaction within a specified timeframe.
Based on FMP financials and quantitative analysis
TDAC Key Highlights
Market capitalization of $267M, reflecting investor valuation of the SPAC's potential acquisition target.
- Incorporated in 2022, indicating a relatively new SPAC seeking a business combination.
- Operates with a small team of 2 employees, highlighting the lean operational structure typical of SPACs.
- P/E ratio of 29.9, which is not directly indicative of performance due to the SPAC's pre-acquisition status.
- Beta of -0.01, suggesting a low correlation with overall market movements, typical for SPACs before a merger announcement.
Who Are TDAC's Competitors?
TDAC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZKPU ZKPU | $10.46 | +4.29% | $262M | 63 |
| OTGAU OTG Acquisition Corp. I Unit | $10.39 | +0.29% | $247M | 65 |
| EVOXU Evolution Global Acquisition Corp | $10.26 | -0.00% | $246M | 63 |
| CMII CM Life Sciences II Inc. | $10.03 | -0.10% | $237M | 65 |
| ITHAU ITHAX Acquisition Corp III | $10.29 | +2.24% | $237M | 62 |
| IRHOR Iron Horse Acquisitions Corp. II Rights | $0.20 | +23.80% | $234M | 63 |
| SVAQU Silicon Valley Acquisition Corp. | $10.48 | +1.45% | $232M | 65 |
| TMTS Spartacus Acquisition Corporation | $10.07 | +0.00% | $232M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TDAC's Key Strengths?
Experienced management team (if applicable).
- Access to capital raised through the IPO.
- Flexibility to target companies in various industries.
- Potential for high returns if a successful merger is completed.
What Are TDAC's Weaknesses?
Dependence on finding a suitable acquisition target.
- Limited operating history.
- Potential for conflicts of interest between management and shareholders.
- Dilution of shareholder value if additional capital is raised.
What Could Drive TDAC Stock Higher?
Announcement of a definitive merger agreement with a target company.
- Successful completion of due diligence on potential target companies.
- Favorable market conditions for SPAC mergers.
What Are the Key Risks for TDAC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 29.9 runs well above the Financial Services sector’s ~18x, leaving little room for a miss.
- Failure to find a suitable acquisition target within the specified timeframe.
- Regulatory changes impacting the SPAC market.
- Economic downturn or market volatility.
- Increased competition from other SPACs.
What Are the Growth Opportunities for TDAC?
- Successful Acquisition: The primary growth opportunity for TDAC lies in its ability to identify and merge with a high-growth private company. The market size of potential target companies is vast, spanning various industries. A well-chosen target with strong fundamentals and growth prospects could drive significant shareholder value post-merger. Timeline: Within the next 12-24 months.
- Favorable Market Conditions: Improved market sentiment and investor appetite for SPAC mergers could create a more conducive environment for TDAC to complete a successful transaction. Positive market conditions can lead to higher valuations and increased investor interest in the merged entity. Market size: Dependent on overall market capitalization and investor confidence. Timeline: Ongoing.
- Strategic Sector Focus: Focusing on a specific high-growth sector, such as technology or healthcare, could increase TDAC's chances of finding an attractive target. Specializing in a particular sector allows the management team to leverage their expertise and network to identify promising opportunities. Market size: Varies by sector. Timeline: Ongoing.
- Operational Efficiency Post-Merger: Implementing operational improvements and cost synergies within the acquired company could enhance profitability and drive shareholder value. Efficient integration and execution are crucial for realizing the full potential of the merger. Market size: Dependent on the acquired company's financials. Timeline: Post-merger.
- Attracting Institutional Investors: Securing commitments from institutional investors prior to the merger could provide additional capital and validation for the transaction. Institutional support can improve the long-term stability and performance of the merged entity. Market size: Institutional investment in SPACs. Timeline: Pre- and post-merger.
What Opportunities Does TDAC Have?
- Growing demand for alternative investment opportunities.
- Increasing number of private companies seeking to go public.
- Favorable market conditions for SPAC mergers.
- Potential to acquire a disruptive or high-growth company.
What Are TDAC's Competitive Advantages?
- Management team's experience and network in identifying and executing successful mergers.
- Access to capital raised through the IPO.
- Speed and efficiency in completing a merger compared to a traditional IPO.
- Flexibility to target companies in various industries.
What Does TDAC Do?
Translational Development Acquisition Corp. (TDAC) is a special purpose acquisition company (SPAC) formed in 2022 and based in New York City. As a shell company, TDAC's primary purpose is to identify and merge with a private company, effectively taking the target company public without the traditional IPO process. TDAC was incorporated with the intention of pursuing a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Unlike operating companies with established products or services, TDAC exists solely to find a suitable acquisition target. The company's success hinges on its management team's ability to identify a promising private company with strong growth potential and negotiate a favorable merger agreement. Once a target is identified, TDAC will typically seek shareholder approval for the proposed merger. If approved, the private company will become a publicly traded entity under the TDAC ticker symbol or a new ticker symbol, depending on the terms of the agreement. TDAC does not have significant operations, with its activities primarily focused on due diligence, negotiation, and regulatory compliance related to potential acquisitions.
What Products and Services Does TDAC Offer?
- Identify potential private companies for a merger or acquisition.
- Conduct due diligence on target companies.
- Negotiate merger agreements.
- Seek shareholder approval for the proposed merger.
- Complete the merger transaction, taking the target company public.
- Manage the transition and integration of the acquired company.
How Does TDAC Make Money?
- Raise capital through an initial public offering (IPO).
- Use the IPO proceeds to fund the acquisition of a private company.
- Generate returns for shareholders through the appreciation of the merged company's stock price.
- Management team typically receives a percentage of the merged company's equity as compensation.
What Industry Does TDAC Operate In?
Translational Development Acquisition Corp. operates within the shell company industry, specifically as a special purpose acquisition company (SPAC). The SPAC market has experienced periods of rapid growth and increased scrutiny. SPACs offer private companies an alternative route to public listing compared to traditional IPOs. The success of a SPAC depends heavily on the quality of the target company it acquires and the prevailing market conditions at the time of the merger. The industry is characterized by high competition among SPACs seeking attractive targets, and regulatory changes can significantly impact the SPAC landscape.
Who Are TDAC's Key Customers?
- Institutional investors seeking exposure to private equity-like returns.
- Retail investors interested in participating in potential high-growth opportunities.
- Private companies seeking a faster and less expensive route to public listing compared to a traditional IPO.
Company Profile
Translational Development Acquisition Corp. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in New York City, US. The company is led by CEO Michael Hoffman. TDAC has traded publicly since 2025.
Financial Health
Translational Development Acquisition Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 20.49 places it in the safe zone, indicating low near-term bankruptcy risk.
Key Financial Metrics
Return on equity for Translational Development Acquisition Corp. stands at 3.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.4%, showing how much profit it generates from its asset base. TDAC trades at a trailing price-to-earnings ratio of 29.88, above the Financial Services sector average of ~18x. Its free cash flow yield is -0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.
TDAC Valuation & Market Position
With a $267M market cap, Translational Development Acquisition Corp. sits in the micro-cap segment of the market. Relative to its peer group, TDAC's quantitative score of 43/100 is below the peer average of 64/100.
TDAC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating a positive outlook among key stakeholders.
- Community sentiment has shifted positively, with discussions highlighting potential growth areas and strategic partnerships.
- Increased interest in SPACs has led to a resurgence in market attention for companies like TDAC, positioning it favorably for upcoming announcements.
- Recent developments in the biotech sector have sparked optimism, aligning with TDAC's focus on innovative health solutions.
Bear Case
- Concerns over the broader SPAC market have led to skepticism, with investors wary of potential regulatory changes affecting future deals.
- Community sentiment remains mixed, with some voices expressing doubts about the company's ability to execute on its strategic plans.
- Recent market volatility has heightened caution among investors, leading to a more bearish outlook on speculative investments like TDAC.
- Lack of concrete financial performance data in the last quarter raises questions about the company's operational viability and long-term prospects.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TDAC Latest News
No recent news available for TDAC.
TDAC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TDAC.
Price Targets
Wall Street price target analysis for TDAC.
TDAC MoonshotScore
What does this score mean?
The MoonshotScore rates TDAC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Michael Hoffman
Managing
Michael Hoffman is the managing person for Translational Development Acquisition Corp., overseeing a small team of two employees. Information regarding his prior professional experience and educational background is not available. His role involves leading the company's efforts to identify and execute a merger with a private company, a process that requires strong financial acumen and deal-making skills.
Track Record: Due to the nature of Translational Development Acquisition Corp. as a SPAC formed in 2022, Michael Hoffman's track record is limited to the company's activities since its inception. There is no information available regarding specific achievements or milestones under his leadership. His success will be determined by his ability to identify and complete a value-accretive merger transaction.
Common Questions About TDAC (Financial Services)
What does the AI Score mean for TDAC?
TDAC holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Translational Development Acquisition Corp. is a shell company focused on identifying and merging with a private business. Incorporated in 2022, the company seeks to create value through a …
What does Translational Development Acquisition Corp. do?
Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC). It does not have any operating business. It was formed to raise capital through an initial public offering (IPO) with the sole purpose of acquiring or merging with an existing private company. The goal is to take the private company public without the traditional IPO process.
What do analysts say about TDAC stock?
As of 2026-05-09, there is limited to no analyst coverage specifically for Translational Development Acquisition Corp. (TDAC) due to its nature as a SPAC prior to announcing a merger target. Any valuation metrics or growth considerations would be speculative until a definitive agreement is reached.
What are the main risks for TDAC?
The primary risk for Translational Development Acquisition Corp. (TDAC) is the failure to identify and complete a merger with a suitable target company within the allotted timeframe, which could lead to the liquidation of the SPAC and the return of capital to shareholders.
What are the key factors to evaluate for TDAC?
Translational Development Acquisition Corp. (TDAC) holds an AI score of 43/100 (low). P/E: 29.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does TDAC data refresh on this page?
TDAC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TDAC's recent stock price performance?
Translational Development Acquisition Corp. (TDAC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team (if applicable). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TDAC overvalued or undervalued right now?
Translational Development Acquisition Corp. (TDAC) trades at 29.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TDAC before investing?
Before investing in Translational Development Acquisition Corp. (TDAC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is limited by the lack of specific information regarding potential acquisition targets.
- Investment in SPACs involves significant risks and should be undertaken with caution.